Article content
Toronto, Ontario–(Newsfile Corp. – April 22, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of the AcuVid™ COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies, is pleased to announce successful preliminary results with its AcuVid™ COVID-19 Rapid Antigen Saliva Test to detect the SARS-CoV-2 Variants of Concern (“VOC”) that are rapidly spreading across Canada and many other countries; specifically the Brazilian P.1 and P.2 and the UK B.1.1.7 variants. The results were obtained in the performance study currently being conducted in Brazil at the Federal University of Minas Gerais (UFMG).
We apologize, but this video has failed to load.
Therma Bright Inc : Therma Bright s AcuVid COVID-19 Rapid Antigen Saliva Test Detects the Important SARS-CoV-2 Variants of Concern; the Brazilian P 1 and P 2 and the UK B 1 1 7 Variants
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Experts see Brazil as breeding ground for new Covid-19 variants
laprensalatina.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from laprensalatina.com Daily Mail and Mail on Sunday newspapers.